Drug development continues to be an expensive and slow endeavour, with high failure rates. AI has the potential to help identify targets and nominate the most promising drugs for testing, but to date, the pharmaceutical industry has very little deep learning in deployment. Building in-house, adaptive AI platforms requires years of investment in software engineering and a deep understanding of the science and technology.
We are incredibly excited to partner with DaltonTx from Day One and support their mission to build adaptive, AI-enabled discovery platforms that reshape the economics, timelines, and outcomes of R&D, to bring breakthrough medicines to patients faster.
Co-founders Dr Garry Pairaudeau, Adrian Rossall, Dr Anthony Bradley and Professor Charlotte Deane MBE have decades of real-world experience combining drug discovery, machine learning, and software engineering expertise. They have built pioneering AI discovery platforms at AstraZeneca and Exscientia and bring world-leading academic research from the University of Oxford.
DaltonTx is based in the heart of London’s tech and life sciences hub at King’s Cross at the intersection of engineering, AI, and drug discovery.
Built by scientists for scientists, DaltonTx goes beyond predictive modelling to power a disease-agnostic self-learning system that integrates seamlessly into scientific workflows and gets smarter with every experiment — from raw data and model training to molecular design, synthesis, and decision-making.
DaltonTx‘s adaptive and collaborative AI platform is purpose-built for both small molecules and biologics. This makes it uniquely suited to support the most complex R&D pipelines. Plugging directly into pharma, biotech, and CRO workflows, teams have instant access to AI-enabled discovery that saves years compared to developing these capabilities in-house. Furthermore, scientists are now able to interact with the system and combine their expertise with an engine that iterates and learns, combining human insight and machine learning.
Dr Garry Pairaudeau, Co-Founder of DaltonTx, comments:
‘AI offers an opportunity to transform drug discovery, but it is still incredibly challenging for organisations to build their own capabilities. DaltonTx exists to change that. We are solving high-impact challenges with adaptive AI-enabled systems that integrate into scientific workflows, evolve with every experiment, and give organisations lasting AI capability.’
Professor Charlotte Deane MBE, Co-Founder of DaltonTx and Professor of Structural Bioinformatics at the University of Oxford, adds:
‘At DaltonTx, we’re generating biological and chemical insight that was previously out of reach. By combining cutting-edge machine learning with deep drug discovery expertise, we are creating technology that learns with every experiment and helps scientists turn ideas into impact.’
On why we partnered with Dalton from Day One, our Partner Tom Wilson, highlights:
‘What impressed us most about DaltonTx is the strength and depth of the founding team. Their unique combination of drug discovery, machine learning, and software engineering expertise positions them to lead the next generation of AI in pharma. We’re proud to back a team with the vision and execution capability to transform how medicines are discovered.’
We are excited to partner with DaltonTx and join their £4 million seed funding round, alongside redalpine and IQ Capital Partners.
For more information, visit daltontx.com.